Cardiovascular disease is a leading cause of morbidity and mortality in patients who have undergone solid organ transplantation. Despite this, limited evidence exists for how to appropriately identify and mitigate cardiovascular risk in this population. In this blog, we discuss the management of dyslipidemia in transplant recipients.
Icosapent Ethyl for Prevention of Cardiovascular Disease: Worth the Hype or Fishing for a Place in Therapy?
Omega-3 fatty acids have been associated with lowering TG; however, robust data for clinical outcomes have been lacking until the recent publication of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT).2,3 This blog will give a brief review of historical evidence, detail differences in fish oil supplements, and provide considerations for the role of Vascepa (icosapent ethyl) in high-risk patients with dyslipidemia.
6 Takeaways from the 2019 Primary Prevention Guideline
There has been a wealth of information in the literature over the past few years about various strategies to prevent cardiovascular disease. Many have been highly anticipating the new primary prevention recommendations from the American College of Cardiology/American Heart Association for guidance on how to apply all of this new evidence. The guidelines have recently been released! A summary of the key takeaways from the Primary Prevention guideline are provided in this blog.
Aspirin for Primary Prevention: Have We ARRIVEd at an Answer?
Evidence from multiple recent trials has brought to question the role of aspirin for primary prevention of cardiovascular disease. This remains common practice in the United States, despite questionable data to identify a population for whom the benefits outweigh the risks. In this blog, I compare recent evidence to current guideline recommendations and speculate whether or not aspirin will have a role for this indication in the future.